Description

This Notice serves to inform sponsors of drug submissions pursuant to Division C.08 of the Food and Drug Regulations (i.e., new drug and abbreviated new drug submissions), of proposed modifications to Health Canada’s comparative bioavailability requirements when multiphasic plasma concentration profiles have been demonstrated to be integral to the product’s therapeutic effect.

Resources

Name	Format	Description	Link
Notice: Proposed Modification to Bioequivalence Standards for Multiphasic Modified-Release Drug Products	HTML		https://www.canada.ca/en/health-canada/services/drugs-health-products/public-involvement-consultations/drug-products/multiphasic-modified-release.html
Notice: Proposed Modification to Bioequivalence Standards for Multiphasic Modified-Release Drug Products	HTML		https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/participation-public-consultations/medicaments/liberation-modifiee-multiphasique.html

Tags

Topics

Categories